Hypomethylation associated enhanced transcription of trefoil factor-3 mediates tamoxifen-stimulated oncogenicity of ER+ endometrial carcinoma cells

Tamoxifen (TAM) is widely used as an adjuvant therapy for women with breast cancer (BC). However, TAM possesses partial oestrogenic activity in the uterus and its use has been associated with an increased incidence of endometrial carcinoma (EC). The molecular mechanism for these observations is not...

Descripción completa

Detalles Bibliográficos
Autores principales: Pandey, Vijay, Zhang, Min, Chong, Qing-Yun, You, Mingliang, Raquib, Ainiah Rushdiana, Pandey, Amit K., Liu, Dong-Xu, Liu, Liang, Ma, Lan, Jha, Sudhakar, Wu, Zheng-Sheng, Zhu, Tao, Lobie, Peter E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652779/
https://www.ncbi.nlm.nih.gov/pubmed/29100386
http://dx.doi.org/10.18632/oncotarget.20461

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652779/
https://www.ncbi.nlm.nih.gov/pubmed/29100386
http://dx.doi.org/10.18632/oncotarget.20461

Ejemplares similares